Arch Therapeutics wins Japanese patent case
Courtesy
Terrence Norchi, Arch president and CEO.
Framingham medical device company Arch Therapeutics said Tuesday a Japanese court has ruled favorably on the validity of its patent license.
The Japanese Intellectual Property High Court ruled to affirm a prior decision of a trial to uphold the patent part of the company’s intellectual property estate Arch has licensed globally and exclusively from the Massachusetts Institute of Technology and Versitech Limited of Hong Kong.
According to Arch, a competitor challenged the patent in a Japanese court, lost and appealed the decision. The High Court affirmed the lower court’s decision on Oct. 30.
“We value both our licensed and internally developed intellectual property,” Arch CEO Terrence Norchi said in a statement. “We appreciate the court’s reaffirmation of the patent rights and reserve the right to protect and defend our technology.”
In the same press release, the company noted its regulatory filings seeking clearance to market its topical gel products in the U.S. and Europe.
“These next weeks, months and quarters are important to Arch as we continue to develop our products for commercialization in the U.S. and Europe,” Norchi said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments